Similar articles

Abstract: Waldenström macroglobulinemia (WM) is characterized by lymphoplasmacytic lymphoma associated with large amounts of monoclonal immunoglobulin M (IgM) protein (Owen et al., 2003). Common signs and symptoms include fatigue due to anemia, lymph node enlargement, hepatosplenomegaly, thrombocytopenia, symptoms related to high viscosity, and peripheral neuropathy, among others. Despite significant advances in WM treatment, this type of indolent lymphoma remains incurable, with a wide array of patient outcomes (Ruan et al., 2020). In recent years, chimeric antigen receptor T (CAR-T) cell therapy targeting cluster of differentiation 19 (CD19) has shown unprecedented response rates and durability in the treatment of B-cell malignancies. In this report, we describe a challenging case of WM that involved multiple extramedullary sites, relapsed, and was refractory to chemotherapy, immunotherapy, and targeted therapy. After anti-CD19 CAR-T cell therapy, the tumor burden significantly decreased and the patient’s condition remained stable at the writing of this report.

华氏巨球蛋白血症：抗CD19嵌合抗原受体T细胞疗法治疗的挑战性病例

[1]AbeykoonJP,ZanwarS,AnsellSM,et al.,2021.Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia.Am J Hematol,96(8):945-953.

[2]BansalR,JurcicJG,SawasA,et al.,2020.Chimeric antigen receptor T cells for treatment of transformed Waldenström macroglobulinemia.Leuk Lymphoma,61(2):465-468.

[3]CastilloJJ,MeidK,FlynnCA,et al.,2020.Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.Blood Adv,4(16):3952-3959.

[4]CastilloJJ,AllanJN,SiddiqiT,et al.,2022.Venetoclax in previously treated Waldenström macroglobulinemia.J Clin Oncol,40(1):63-71.

[5]GertzMA,2023.Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.Am J Hematol,98(2):348-358.

[6]KastritisE,MorelP,DuhamelA,et al.,2019.A revised international prognostic score system for Waldenström’s macroglobulinemia.Leukemia,33(11):2654-2661.

[7]KyriakouC,2018.High-dose therapy and hematopoietic stem cell transplantation in Waldenström macroglobulinemia.Hematol Oncol Clin North Am,32(5):865-874.

[8]LockeFL,GhobadiA,JacobsonCA,et al.,2019.Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.Lancet Oncol,20(1):31-42.

[9]OwenRG,TreonSP,Al-KatibA,et al.,2003.Clinicopathological definition of Waldenstrom’s macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia.Semin Oncol,30(2):110-115.

[10]PalombaML,QuallsD,MonetteS,et al.,2022.CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience.J Immunother Cancer,10(2):e004128.

[11]RuanG,ZanwarS,AbeykoonJP,et al.,2020.Predictors of short-term survival in Waldenström macroglobulinemia.Leuk Lymphoma,61(12):2975-2979.

[12]ShadmanM,YeungC,RedmanMW,et al.,2023.CD20 CAR-T therapy with MB-106 for BTK inhibitor-refractory Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) ‒ single institution study. HemaSphere,7(S3):e68877ca.

[13]ThompsonPA,TamCS,2023.Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders.Blood,141(26):3137-3142.

[14]TreonSP,2015.How I treat Waldenström macroglobulinemia.Blood,126(6):721-732.

[15]TreonSP,TedeschiA,San-MiguelJ,et al.,2023.Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom’s macroglobulinemia on diagnostic and response criteria.Semin Hematol,60(2):97-106.